Regulatory Classification of Non-Interventional Studies: When Do They Require Approval?

Published on 21/12/2025

Understanding When Non-Interventional Phase 4 Studies Require Regulatory Approval

Table of Contents

Introduction

Not all clinical research conducted post-approval is interventional. In Phase 4 clinical trials, many studies fall under the category of non-interventional studies (NIS), where the treatment is prescribed as per routine clinical practice. However, there’s often confusion about when such studies require regulatory approvals. Understanding the criteria, definitions, and region-specific expectations is crucial for both compliance and operational efficiency.

This tutorial provides a clear framework for identifying whether a non-interventional study in Phase 4 needs regulatory approval, supported by global regulatory standards and real-world examples.

What Is a Non-Interventional Study?

A non-interventional study (also called observational study) is defined by regulatory authorities as a study where:

The medicinal product is prescribed in the usual manner in accordance with the terms of the marketing authorization
The assignment of the patient to a particular therapeutic strategy is not decided in advance by a trial protocol
No additional diagnostic or monitoring procedures are applied to the patients
The epidemiological methods are used for data analysis

These studies are used to collect real-world data (RWD) to support effectiveness, safety, adherence, and pharmacoeconomic outcomes.

When Do NIS Require Approval?

Although NIS are generally exempt from full

clinical trial authorization, some conditions still trigger a need for notification or approval depending on the regulatory region:

1. If the Study Involves Additional Procedures

Any additional blood draw, imaging, or diagnostic test beyond routine care may classify the study as interventional

2. If Patients Are Randomized or Assigned to Treatment

Assignment that isn’t part of standard medical care removes the study from NIS classification

3. If the Product Is Not Yet Approved

Any observational study using an unapproved product becomes a clinical trial by definition

Country-Wise Regulatory Overview

United States (FDA)

NIS typically do not require IND or IRB approval unless:
- Data collection involves procedures beyond standard care
- There is an intention to use the data to support regulatory filings
Good Clinical Practice (GCP) guidelines are recommended but not mandatory

European Union (EMA)

As per Regulation (EU) No 536/2014, NIS are not subject to the same requirements as clinical trials
However, if the study qualifies as a PASS (Post-Authorization Safety Study), submission to EMA is required
Mandatory registration in the EU PAS Register

India (CDSCO)

As per New Drugs and Clinical Trials Rules (2019), NIS do not require prior approval if:
- Conducted as per standard of care
- No off-label indications or unapproved combinations are used
Recommended to register in the Clinical Trials Registry of India (CTRI) for transparency

Japan (PMDA)

Real-world studies or registries that observe standard care are permitted without IND
However, studies funded by marketing authorization holders (MAHs) must meet GPSP requirements

Types of NIS in Phase 4 That May Require Review

Post-Authorization Safety Studies (PASS) mandated by EMA or PMDA
Registry-based studies using longitudinal patient tracking
Market authorization extension studies using real-world data to support label expansion

Real-World Example: Metformin Observational Study

A non-interventional observational cohort study was conducted in India to monitor long-term renal function in diabetic patients taking Metformin. Since no additional tests were done, no regulatory approval was needed—but CTRI registration was completed for transparency. However, had the study included renal biopsies, it would have required CDSCO clearance.

Best Practices for Sponsors and Investigators

Check national and regional definitions carefully before classifying a study as non-interventional
Register studies voluntarily even if approval isn’t mandated
Have a documented justification for classifying a study as non-interventional
Use observational study protocols aligned with ENCePP (EU) and STROBE standards

Documentation to Prepare for NIS

Study protocol clearly stating observational nature
Data privacy and GDPR compliance plan
Informed consent form if identifiable data is collected
Site training on GPP (Good Pharmacoepidemiology Practices)

Ethical Oversight for NIS

Even if regulatory approval isn’t needed, many countries still require Ethics Committee/IRB clearance for observational studies. This ensures patient protection, especially for long-term follow-up or use of identifiable data.

Final Thoughts

Not all Phase 4 research is created equal—and not all of it needs regulatory approval. However, making that determination requires a solid understanding of both the study design and the applicable regulatory framework. Sponsors and academic institutions must carefully assess their studies’ scope, document their classification rationale, and engage with local authorities when needed.

At ClinicalStudies.in, we help research teams streamline compliance and protocol development for non-interventional Phase 4 studies across global jurisdictions.